Basic Research

MicroRNA-29a Promotion of Nephrin Acetylation Ameliorates Hyperglycemia-Induced Podocyte Dysfunction

Chun-Liang Lin, Pei-Hsien Lee, Yung-Chien Hsu, Chen-Chou Lei, Jih-Yang Ko, Pei-Chin Chuang, Yu-Ting Huang, Shao-Yu Wang, Shin-Long Wu, Yu-Shan Chen, Wen-Chih Chiang, Jochen Reiser and Feng-Sheng Wang
JASN August 2014, 25 (8) 1698-1709; DOI: https://doi.org/10.1681/ASN.2013050527

Abstract

Podocyte dysfunction is a detrimental feature in diabetic nephropathy, with loss of nephrin integrity contributing to diabetic podocytopathy. MicroRNAs (miRs) reportedly modulate the hyperglycemia-induced perturbation of renal tissue homeostasis. This study investigated whether regulation of histone deacetylase (HDAC) actions and nephrin acetylation by miR-29 contributes to podocyte homeostasis and renal function in diabetic kidneys. Hyperglycemia accelerated podocyte injury and reduced nephrin, acetylated nephrin, and miR-29a levels in primary renal glomeruli from streptozotocin-induced diabetic mice. Diabetic miR-29a transgenic mice had better nephrin levels, podocyte viability, and renal function and less glomerular fibrosis and inflammation reaction compared with diabetic wild-type mice. Overexpression of miR-29a attenuated the promotion of HDAC4 signaling, nephrin ubiquitination, and urinary nephrin excretion associated with diabetes and restored nephrin acetylation. Knockdown of miR-29a by antisense oligonucleotides promoted HDAC4 action, nephrin loss, podocyte apoptosis, and proteinuria in nondiabetic mice. In vitro, interruption of HDAC4 signaling alleviated the high glucose–induced apoptosis and inhibition of nephrin acetylation in podocyte cultures. Furthermore, HDAC4 interference increased the acetylation status of histone H3 at lysine 9 (H3K9Ac), the enrichment of H3K9Ac in miR-29a proximal promoter, and miR-29a transcription in high glucose–stressed podocytes. In conclusion, hyperglycemia impairs miR-29a signaling to intensify HDAC4 actions that contribute to podocyte protein deacetylation and degradation as well as renal dysfunction. HDAC4, via epigenetic H3K9 hypoacetylation, reduces miR-29a transcription. The renoprotective effects of miR-29a in diabetes-induced loss of podocyte integrity and renal homeostasis highlights the importance of post-translational acetylation reactions in podocyte microenvironments. Increasing miR-29a action may protect against diabetic podocytopathy.

Podocytopathy in renal tissue is an important event of glomerular dysfunction that results in diabetes-mediated proteinuria and renal disorders.1,2 Glomerular damage in diabetic kidneys has been linked to hyperglycemia-induced promotion of podocyte dedifferentiation3 and apoptosis,4 as well as disturbance of angiogenic responses5 and mitochondrial fission in podocyte microenvironments.6

Nephrin acts as an important slit diaphragm protein that orchestrates interaction between cellular junctions and cytoskeleton dynamics in podocytes.7 On the other hand, lack of nephrin has been observed to result in glomerular deterioration and proteinuria.8 Defective nephrin integrity is a prominent feature in hyperglycemia-mediated podocyte injury that accelerates glomerular damage in vivo and reduces podocyte viability in vitro.9,10 Accumulating evidence demonstrates that post-translational modification of nephrin, including phosphorylation,11 ubiquitination,12 or sialylation,13 modulates podocyte functions in various physiologic or pathologic conditions.14 However, the biologic role of nephrin acetylation in diabetic podocytopathy has scarcely been addressed.

Histone deacetylase 4 (HDAC4), one of the class II HDACs, has been found to modify acetylation reactions in histones or nonhistone proteins and has been reported to regulate glucose homeostasis,15 neuron plasticity,16 degenerative neural disorders,17 and hepatic carcinoma.18 Administration of HDAC inhibitors ameliorates both adriamycin-induced renal injury19 and diabetes-induced glomerular hypertrophy.20 The contribution of HDAC4 signaling to nephrin stability in the progression of diabetes-induced podocyte injury is worthy of characterization.

MicroRNAs (miRs) are short and noncoding RNAs that have been observed to not only interrupt protein translation through the degradation of mRNA targets,21 but to also regulate homeostasis and deterioration of renal tissues. Loss of miR-192 signaling accelerates fibrotic matrix deposition in diabetic kidneys,22 whereas a decrease in miR-29 signaling accelerates TGF-β1–mediated renal fibrosis reactions.23 It has also been reported that miR-29s regulate HDAC actions in myogenic differentiation24 and acute myeloid leukemia.25 We previously demonstrated that nephrin destabilization reduced podocyte survival and accelerated diabetes-induced renal damage.26 We propose that miR-29a interacts with HDAC signaling to regulate the nephrin acetylation, podocyte integrity, and renal function in diabetic mice.

This study investigated the acetylation status of nephrin, podocyte integrity, and renal function in diabetic miR-29a transgenic and wild-type mice. We also verified whether HDAC4 was involved in hyperglycemia-induced perturbation of nephrin acetylation and miR-29a signaling in podocyte cultures.

Results

Diabetes Reduced Nephrin Acetylation, Podocyte Survival, and miR-29a Expression

We utilized streptozotocin-induced hyperglycemic mice to test whether diabetes-mediated podocyte destruction was linked to the acetylation status of nephrin. Hyperglycemia significantly increased urinary protein excretion throughout the study period (Figure 1A). Podocytes in the diabetes group strongly displayed the podocyte injury marker desmin immunostain and the apoptotic cell marker terminal deoxynucleotidyl transferase–mediated digoxigenin-deoxyuridine nick-end labeling (TUNEL) stain (Figure 1B). Few podocytes in diabetic kidneys weakly expressed cell markers nephrin and Wilm's tumor-1 protein (WT-1) immunoreactions at 12 weeks after hyperglycemia compared with the normal control kidneys (Figure 1C). We harvested renal glomeruli to detect miR-29a expression and isolate nephrin immunoprecipitates; we also probed the immunocomplexes by acetylated lysine antibodies to identify acetylated nephrin. Diabetes significantly decreased the levels of nephrin, acetylated proteins, and acetylated nephrin throughout the study period (Figure 1D). Quantitative RT-PCR analyses revealed that diabetes significantly reduced the expression of miR-29a, but not miR-29b or miR-29c in renal glomeruli throughout the study period (Figure 1E). In situ hybridization observations showed that miR-29a transcripts were detectable in podocytes and tubular cells of the normal control kidneys, whereas few podocytes in diabetic kidneys expressed the miR-29a transcripts. However, podocytes and tubular cells in normal and diabetic kidneys ubiquitously expressed miR-29b and miR-29c transcripts (Figure 1F). Given that miR-29a reportedly regulates tissue fibrosis and protein acetylation,23,24 it was selected for the following experiments.

Figure 1.
Figure 1.

Effects of hyperglycemia on podocyte integrity and miR-29 expression in kidneys. (A) Diabetes increases urinary protein levels. (B and C) Podocytes in diabetic kidneys strongly display desmin immunoreactivity and TUNEL stain (arrows) (B) and weakly express nephrin and WT-1 (arrows) immunofluorescence (C). (D and E) Diabetes reduces the levels of nephrin, acetylated protein, and acetylated nephrin (D) and the expression of miR-29a (E). (F) miR-29a, miR-29b, and miR-29c are detectable in podocytes (arrows) and tubular cells (arrowheads) of normal kidneys. Few podocytes and tubular cells in diabetic kidney weakly display miR-29a transcripts. Data are expressed as the mean±SEM calculated from eight mice at each time point. *P<0.05, significant difference from the normal control group. Ac-lysine, acetylated lysine; DM, diabetic mice; IB, immunoblotting; IP, immunoprecipitates; NC, normal control.

Gain of miR-29a Function Improved Renal Function and Podocyte Survival

We investigated whether miR-29a overexpression changed diabetes-induced podocytopathy and created miR-29a transgenic mice expressing a human phosphoglycerate kinase (PGK) promoter–coded miR-29a precursor. Agarose gel electrophoretography revealed that renal glomeruli constitutively expressed the miR-29 precursor construct corresponding to 506 bp (Figure 2A). Quantitative RT-PCR analyses confirmed that renal glomeruli in transgenic mice had higher miR-29a expression than that in wild-type mice (Figure 2A). Podocytes and tubular cells in transgenic mice with or without diabetes strongly expressed miR-29a transcripts compared with that in wild-type mice (Figure 2B). All animals gained body weight throughout the study period (Figure 2C). There was no significant difference in BUN, creatinine, cholesterol, creatine phosphokinase, glutamic pyruvic transaminase, Na, K, or Cl levels in sera between miR-29a transgenic mice and wild-type mice with or without diabetes (Supplemental Material). miR-29a overexpression did not significantly change the diabetes promotion of blood glucose (Figure 2D) or hemoglobin A1c (Figure 2E) levels. Of note, miR-29a overexpression significantly reduced the diabetes-induced hyperfiltration as evidenced by increased creatinine clearance at 4 weeks after hyperglycemia (Figure 2F), and decreased kidney weight (Figure 2G) and urinary protein levels (Figure 2H) at 8 weeks after hyperglycemia compared with wild-type mice.

Figure 2.
Figure 2.

Effect of miR-29a overexpression on miR-29a expression and renal function. (A) hPGK promoter-coded full-length 506 bp miR-29a precursors are constructed. Transgenic mice with or without diabetes have higher miR-29a expression in renal glomeruli than that of wild-type mice. (B) Podocytes (arrows) and tubular cells in transgenic mice strongly display the miR-29a transcript. (C–E) There is no significant difference in body weight (C), blood glucose (D), or HbA1c (E) levels between the transgenic mice and wild-type mice with diabetes. (F–H) Overexpression of miR-29a reduces diabetes-induced hyperfiltration (F), kidney weight loss (G), and urinary protein secretion (H). Data are expressed as the mean±SEM calculated from six to eight mice at each time point. *P<0.05, significant difference versus the NC group; #P<0.05, significant difference versus wild-type group. CCR, creatinine clearance; DM, diabetic mice; HbA1c, hemoglobin A1c; NC, normal control; PC, positive control; STZ, streptozotocin; Tg, transgenic mice; WT, wild-type mice.

Glomeruli in diabetic kidneys underwent hypertrophy and strongly displayed periodic acid–Schiff stain. The miR-29a overexpression reduced diabetes-mediated glomerular hypertrophy and periodic acid–Schiff stain (Figure 3A). Few podocytes and tubular cells in the diabetic kidneys of the transgenic mice weakly expressed desmin immunoreactivity (Figure 3B) and TUNEL stain (Figure 3C) compared with the diabetic kidneys in wild-type mice. By contrast, podocytes in the transgenic mice with or without diabetes strongly expressed nephrin (Figure 3D) and WT-1 (Figure 3E) immunofluorescence reactions. Immunoblotting and quantitative RT-PCR analyses showed that miR-29a overexpression attenuated the diabetes-induced loss of nephrin and WT-1 (Figure 3F) and decreased the expression of fibrogenic factors TGF-β1, fibronectin, and IL-1β in diabetic renal glomeruli (Figure 3G).

Figure 3.
Figure 3.

Effect of miR-29a overexpression on glomerular fibrosis and podocyte integrity of diabetic kidneys. (A) Overexpression of miR-29a reduces the diabetes promotion of PAS-stained renal glomeruli. (B–E) Podocytes in diabetic kidneys of transgenic mice weakly express desmin immunoreactivity (B) and TUNEL stain (arrows) (C), and strongly express nephrin (D) and WT-1 immunofluorescence (E). (F and G) Overexpression of miR-29a attenuates diabetes-induced nephrin and WT-1 loss (arrows) (F) and the expression of TGF-β1, fibronectin, and IL-1β in renal glomeruli (G). *P<0.05, significant difference versus the NC group; #P<0.05, significant difference versus the wild-type group. Mean glomerular volume (GV; μm3/106) was calculated according to the Weibel and Gomez formula. DM, diabetic mice; NC, normal control; PAS, periodic acid–Schiff; Tg, transgenic mice; WT, wild-type mice.

miR-29a Modulated HDAC Expression and Nephrin Acetylation

We isolated nephrin immunoprecipitates from renal glomerular extracts and tested whether miR-29a signaling changed the acetylation status of nephrin. Electrophoretograms and liquid chromatography–tandem mass spectrometry analyses showed that a protein corresponding to 120 kD presented in the nephrin immunoprecipitates (Figure 4A) and the protein of interest showed high homology with HDAC4 (Figure 4A). Bioinformatics searches indicate that HDAC4, HDAC7a, and histone acetyltransferase p300/CBP-associated factor (PCAF) are predicated as putative miR-29a targets (http://www.microrna.org). Diabetes significantly increased HDAC4 (Figure 4B) and reduced acetylated nephrin levels (Figure 4C); miR-29a overexpression significantly reduced the promotion of HDAC4 levels (Figure 4B) and restored acetylated nephrin concentrations (Figure 4C). There was no significant difference in HDAC7A or PCAF levels between the miR-29a transgenic mice and wild-type mice with or without diabetes (data not shown).

Figure 4.
Figure 4.

Effect miR-29a overexpression on HDAC level and nephrin acetylation in renal glomeruli. (A) Electrophoretography and liquid chromatography–tandem mass spectrometry spectrum of HDAC4. (B) miR-29a overexpression reduces the diabetes promotion of HDAC4 levels but not the HDAC7A or PCAF level. (C–E) Overexpression of miR-29a increased acetylated nephrin levels (C) and reduced ubiquitinated nephrin levels (D) in renal glomeruli and urinary nephrin excretion in diabetic kidneys (E). Data are expressed as the mean±SEM calculated from six to eight mice in each group. *P<0.05, significant difference versus the NC group; #P<0.05 indicates significant difference versus the wild-type group. Ac-lysine, acetylated lysine; Ac-nephrin, acetylated nephrin; DM, diabetic mice; IB, immunoblotting; IP, immunoprecipitates; MM, molecular mass; NC, normal control; PCAF, P300/CBP-associated factor; PI, isoelectric point; Tg, transgenic mice; Ub-nephrin, ubiquitinated nephrin; WT, wild-type mice.

We tested whether diabetes-induced nephrin loss was linked to ubiquitination. Nephrin immunoprecipitates were probed by ubiquitin mAbs to indicate ubiquitinated nephrin corresponding to 100 kD. In the wild-type mice, diabetes significantly increased ubiquitinated nephrin levels (Figure 4D) and urinary nephrin levels (Figure 4E) compared with normal control mice. These effects were significantly reduced in miR-29a transgenic mice.

Histologic observation revealed that few podocytes in diabetic kidneys of wild-type mice weakly expressed immunoreactivity of nephrin (green fluorescence) and acetylated lysine (red fluorescence) compared with those of the normal control group (Figure 5). Podocytes in transgenic mice with or without diabetes strongly displayed nephrin and acetylated lysine immunofluorescence reactions (Figure 5).

Figure 5.
Figure 5.

Representative immunofluorescence images of nephrin and acetylated lysine in renal glomeruli of miR-29a transgenic mice and wild-type mice. Podocytes strongly display nephrin immunofluorescence (green fluorescence) and acetylated-lysin immunoreactions (red fluorescence) in transgenic mice. DAPI, 4′,6-diamidino-2-phenylindole; DM, diabetic mice; NC, normal control; Tg, transgenic mice; WT, wild-type mice.

Knockdown of miR-29a Promoted Podocyte Apoptosis and Nephrin Deacetylation

We tested whether knockdown of miR-29a affected nephrin stability or podocyte integrity. Exogenous miR-29a antisense oligonucleotides significantly reduced miR-29a expression (Figure 6A). Few podocytes and tubular cells in renal glomeruli expressed miR-29a transcripts (Figure 6B), whereas podocytes and tubular cells strongly displayed desmin immunostain and TUNEL stain (Figure 6C) at 8 weeks after treatment. The miR-29a interruption significantly reduced the levels of nephrin and acetylated nephrin, but increased the levels of HDAC4 and ubiquitinated nephrin (Figure 6D) and excretion of urinary nephrin and protein (Figure 6E) compared with those of the control group. Empty vector treatment did not significantly affect either the levels of HDAC4 or nephrin or secretion of urinary nephrin or protein.

Figure 6.
Figure 6.

Effect of exogenous miR-29a antisense oligonucleotide on podocyte survival and renal function. (A) The miR-29a antisense oligonucleotide decreases miR-29a expression in renal glomeruli. (B and C) Podocytes (arrows) and tubular cells weakly express miR-29a transcripts (B) and strongly express desmin immunoreactivity and TUNEL stain (arrows) (C). (D) Knockdown of miR-29a reduces nephrin and acetylated nephrin and increases the levels of HDAC4 and ubiquitinated nephrin. (E) Knockdown of miR-29a increases the excretion of urinary nephrin and protein. Data are expressed as the mean±SEM calculated from six mice in each group. *P<0.05, significant difference versus empty vector group. Ac-nephrin, acetylated nephrin; AS, miR-29a antisense oligonucleotide; IB, immunoblotting; IP, immunoprecipitates; NC, normal control; Ub-nephrin, ubiquitinated nephrin; Vector, empty vector.

HDAC4 Interference Reduced High Glucose–Induced Nephrin Loss and Apoptosis in Podocyte Cultures

We incubated primary mouse kidney podocytes and immortalized podocyte cultures in high glucose conditions to test whether miR-29a or HDAC4 regulated podocyte injury. High glucose treatment significantly reduced the levels of nephrin, WT-1, and acetylated nephrin and increased the levels of HDAC4 and ubiquitinated nephrin in primary podocytes (Figure 7A) and immortalized podocyte cultures (Figure 7B). Transfection of miR-29a precursor or HDAC4 RNA interference (RNAi) significantly reduced the high glucose promotion of HDAC4 and ubiquitinated nephrin levels and restored nephrin, WT-1, and acetylated nephrin levels in primary podocytes (Figure 7A, Supplemental Material) and immortalized podocyte cultures (Figure 7B, Supplemental Material). Protein ligation analyses revealed that podocytes positive for nephrin and HDAC4 ligation displayed red fluorescence in the cytoplasm. Cell cultures incubated in high glucose conditions strongly displayed fluorescence reactions (Figure 7C) and green fluorescence TUNEL staining (Figure 7D). These effects were reduced after miR-29a precursor or HDAC4 RNAi treatment. Neither scramble control nor osmolarity control mannitol significantly changed the levels of nephrin, WT-1, or HDAC4 or apoptosis in podocytes.

Figure 7.
Figure 7.

Effects of miR-29a precursor and HDAC4 siRNA on nephrin acetylation in high glucose–stressed podocyte cultures. (A and B) The miR-29a precursor and HDAC4 RNAi attenuates the high glucose promotion of HDAC4 and ubiquitinated nephrin levels and increases the levels of nephrin and acetylated nephrin in primary podocytes (A) and immortalized podocyte cultures (B). (C and D) Representative images of ligation between HDAC4 and nephrin (C) and TUNEL fluorescence stain in podocytes (D). Podocytes in the miR-29a precursor and HDAC4 RNAi group weakly display HADC4 and nephrin ligation and TUNEL stain. Data are expressed as the mean±SEM calculated from at least three repeated experiments. *P<0.05, significant difference versus scrambled control group; #P<0.05, significant difference versus high glucose group. Ac-lysine, acetylated lysine; Ac-nephrin, acetylated nephrin; HG, high glucose; IB, immunoblotting; IP, immunoprecipitates; NC, normal control; PLA, proximity ligation assay; siRNA, small interfering RNA; Ub-nephrin, ubiquitinated nephrin.

HDAC4 Regulated miR-29a Transcription

We tested whether HDAC4 changed histone acetylation or miR-29a expression in podocyte cultures. High glucose significantly reduced the levels of acetylated histone H3 at the lysine 9 site (H3K9Ac), whereas the miR-29a precursor or HDAC4 RNAi transfection significantly restored H3K9Ac levels in primary podocytes (Figure 8A) and immortalized podocyte cultures (Figure 8B). Chromatin immunoprecipitation-quantitative PCR analyses confirmed that the H3K9Ac antibodies were specific for detecting the H3K9Ac enrichment in the miR-29a proximal promoter (Figure 8C). High glucose significantly decreased the levels of H3K9Ac in the miR-29a proximal promoter region in primary podocytes (Figure 8C) and immortalized podocyte cultures (Figure 8D). The miR-29a precursor or HDAC4 RNAi significantly increased the enrichment of H3K9Ac in the miR-29a promoter. Moreover, the miR-29a precursor or HDAC4 RNAi significantly increased miR-29a transcription in both primary podocytes (Figure 8E) and immortalized podocyte cultures (Figure 8F) exposed to high glucose.

Figure 8.
Figure 8.

Effect of miR-29 and HDAC4 signaling on H3K9 acetylation and miR-29a transcription in podocyte cultures. (A and B) The miR-29a precursor and HDAC4 RNAi reduces the high glucose inhibition of H3K9Ac levels in primary podocytes (A) and immortalized podocyte cultures (B). (C and D) The miR-29a precursor and HDAC4 RNAi increases the enrichment of H3K9AC on the miR-29a proximal promoter region in primary podocytes (C) and immortalized podocyte cultures (D). (E and F) The miR-29a precursor and HDAC4 RNAi increases miR-29a transcription in high glucose–stressed primary podocytes (E) and immortalized podocyte cultures (F). Data are expressed as the mean±SEM calculated from at least three repeated experiments. *P<0.05, significant difference versus scrambled control group; #P<0.05, significant difference versus high glucose group. GADPH, glyceraldehyde 3-phosphate dehydrogenase; HG, high glucose; siRNA, small interfering RNA.

Discussion

Podocyte loss and dysfunction in renal microenvironments are important features in the pathogenesis of diabetic nephropathy.27 Podocyte nephrin disintegration in the slit diaphragm has been observed to contribute to loss of protein filtration capacity resulting in excessive urinary protein excretion.1 However, post-translational acetylation events underlying diabetes-induced loss of podocyte integrity have not yet been elucidated. In this study, we demonstrated that hyperglycemia-induced deacetylation and ubiquitination reactions on the podocyte microstructure deteriorated podocyte homeostasis and renal function in diabetic mice. Interplay between miR-29a and HDAC4 signaling modulated the acetylation status of podocyte microenvironments and counteracted against the diabetes-induced podocyte damage, glomerular fibrosis and inflammation, and renal dysfunction. This study marks the first attempt to shed light on both nephrin acetylation in the stabilization of podocyte function and epigenetic actions on maintaining nephrin stability and renal podocyte integrity in diabetic kidneys.

Diabetic kidneys in the miR-29a transgenic mice had better podocyte and tubular cell viability and lower fibrogenic factor expression and urinary protein secretion than those of the wild-type mice, suggesting that protective effects triggered by miR-29a signaling occur in renal microenvironments. Exogenous miR-29a antisense oligonucleotide induction of podocyte injury and excessive urinary protein levels in nondiabetic mice also support the postulation that miR-29a signaling is beneficial for maintaining renal homeostasis. The results of our analysis agree with previous studies demonstrating that miR-29a is a potent regulator that inhibits fibrotic matrix expression in high glucose–stressed renal proximal tubule cells.28 However, the biologic roles of the miR-29 family in renal function remain unclear. Muscle wasting–mediated CKD is associated with the decreased expression of miR-29a and miR-29b.29 In addition, miR-29b has been found to ameliorate fibrosis reactions in tubular epithelial cells and obstructive nephropathy.23 TGF-β1 decreases the expression of miR-29b and miR-29c but not miR-29a in immortalized human podocyte cultures.30 By contrast, knockdown of miR-29c reduces high glucose–induced apoptosis in mouse podocytes and attenuates albuminuria and mesangial fibrosis in db/db mice.31 Urinary miR-29b and miR-29c further correlate with proteinuria in patients with IgG nephropathy.32 In this study, miR-29a, but neither miR-29b nor miR-29c, in renal glomerular microenvironments actively responded to hyperglycemic stress. Moreover, miR-29a signaling reduced diabetes-induced podocyte and tubular cell apoptosis, renal fibrosis, and proteinuria. We speculate that different kidney disease models may have varying expression of the miR-29 family in renal microenvironments. Each miR-29 family member may have its own distinct biologic action on renal tissue remodeling. These phenomena rationalize our hypotheses to focus on the molecular events underlying miR-29a protection against diabetes-mediated podocyte dysfunction.

Our experimental results revealed that diabetes led to a reduction in the nephrin level in conjunction with nephrin deacetylation. Whereas nephrin has been shown to act as a potent tyrosin kinase that triggers biologic reactions in maintaining podocyte function and renal filtration capacity in various renal disorders,9,14,33,34 podocyte nephrin acetylation in diabetic kidneys has seldom been delineated until now. This study suggests that miR-29a antisense oligonucleotide-induced nephrin deacetylation impedes podocyte integrity in nondiabetic kidneys. Conversely, restoration of acetylated nephrin by miR-29a overexpression alleviated the diabetes-mediated podocyte injury and renal function. We are the first group to report the biologic action of noncoding miR signaling on nephrin acetylation in podocyte microenvironments. Nephrin ubiquitination and urinary nephrin excretion also explain the phenomenon of diabetes-induced nephrin loss causing podocyte microarchitecture destabilization.

Immunoprecipitation and liquid chromatography–tandem mass spectrometry analyses revealed that acetylation regulators PCAF, HDAC7a, and HDAC4 presented in the nephrin immunocomplexes. HDAC4 actively responded to hyperglycemic stress and miR-29a signaling and contributed to hyperglycemia-mediated loss of nephrin acetylation reactions and viability in podocytes. HDAC4 was found to be essential for embryonic kidney development35 and the regulation of angiogenic reactions in kidney cancer cells.36 Protein ligation analyses also confirmed the interaction between HDAC4 and nephrin in high glucose–stressed podocyte cultures. This study highlights the new molecular insight that HDAC4-dependent nephrin loss augments hyperglycemia-mediated podocyte destruction.

This study demonstrates that high glucose reduced both levels of H3K9Ac as well as the enrichment of H3K9Ac in the miR-29a proximal promoter region. Emerging evidence has proven that HDAC4 signaling regulates miR-mediated somatic cell reprogramming37 and keratinocyte senescence,38 as well as represses the miR-29b action in chronic lymphocytic leukemia.39 It is noteworthy that this study revealed that HDAC4 interruption restored H3K9Ac enrichment in the miR-29a promoter region and increased miR-29a transcription in high glucose–stressed podocyte cultures. The experimental results provide a new perspective that HDAC4 via an epigenetic pathway represses miR-29a transcription in the progression of high glucose–induced podocyte injury. Disturbed orchestration between miR-29a and HDAC4 signaling accelerates glomerular podocyte and renal deterioration. We do not exclude the possibility that miR-29a signaling may change post-translational modification or survival of other bioactive proteins or renal cell populations. Upregulation of podocyte marker WT-1 and tubular cell viability and reduction of glomerular fibrosis and inflammation in diabetic kidneys of miR-29a transgenic mice also reflect the diverse functions of miR-29a signaling on renal glomerular homeostasis.

Taken together, miR-29a is an important regulator in the maintenance of podocyte ultrastructure integrity and renal homeostasis. By suppressing HDAC4 action, miR-29a restores the acetylation status of nephrin and protects against diabetes-induced podocyte injury and renal dysfunction. HDAC4-dependent H3K9 hypoacetylation counteracts miR-29a transcription in high glucose–stressed podocytes (Figure 9). This study highlights an emerging view of an epigenetic mechanism underlying nephrin acetylation in podocytes and suggests that the addition of the miR-29a function is beneficial for improving diabetic podocytopathy.

Figure 9.
Figure 9.

Scheme of miR-29a signaling protection against diabetes-induced podocyte injury and renal dysfunction. miR-29a signaling attenuates the promoting effects of hyperglycemia on HDAC4-dependent nephrin deacetylation and ubiquitination and WT-1 integrity loss that accelerates podocyte apoptosis, proteinuria, and renal fibrosis. HDAC4 modulation of H3K9 hypoacetylation impedes miR-29a transcription in high glucose–stressed podocytes.

Concise Methods

Streptozotocin-Induced Diabetes

Three-month-old male FVB mice were given 50 mg/kg streptozotocin to induce hyperglycemia, as previously described.40 At 2 weeks after streptozotocin treatment, animals with postfast blood glucose of 200–300 mg/dl were considered diabetic. Blood glucose in animals was equalized by insulin.41 Diabetic or normal animals were euthanized by an overdose of sodium pentobarbital at 4 weeks (n=8), 8 weeks (n=8), and 12 weeks (n=8) after diabetes. All protocols for animal use and experiment were approved by the Institutional Animal Care and Use Committee of Chang Gung Memorial Hospital, Taiwan.

miR-29a Transgenic Mice

The PGK promoter and miR-29a precursor full-length sequence were cloned from the cDNA library by PCR protocols. The cDNAs were inserted into the pUSE empty expression vector; and the linear human PGK-miR-29a-BGH poly-A cDNAs were cloned. The designed constructs were transferred into fertilized eggs from FVB/N mice. The eggs were further transferred into Crl:CD1 foster mothers, as previously described.42 Transgenic mice were bred in a specific pathogen-free condition and genotyped by PCR using specific primers (forward: 5′-GAGGATCCCCTCAAGGATACCAAG-GGATGAAT-3′ and reverse 5′-CTTCTAGAAGGAGTGTTTCTAGGTATCCGT-CA-3′).

Lentivirus-Mediated miR-29a Inhibitor Treatment

miR-29a antisense oligonucleotide constructs were inserted into pMIF-cGFP-zeo and pmiR-ZIP shRNA expression vectors and transfected with pPACKF1 vector into 293T cells, according to the manufacturer’s instructions (System Biosciences, Mountain View, CA). Titers of lentivirus were measured using the plaque-forming method. Anesthetized mice were given 109 pfu/kg miR-29a antisense oligonucleotide (n=8), empty vector (n=8), or vehicle (n=8) via tail vein. At 8 weeks after injection, animals were euthanized and renal tissues were dissected for studies.

Urine and Serum Biochemistry

Serum hemoglobin A1c and blood glucose levels were detected according to the manufacturer’s instructions (Primus Diagnostics, Kansas City, MO). Urine excretion of each animal was collected using a metabolic cage system. Total protein (Dade Behring, Inc., Newark, NJ), creatinine (Formosa Biomedical Technology Corp., Taipei, Taiwan), and nephrin (Life Science, Inc., Houston, TX) concentrations in urine were measured using the respective kits. In some experiments, BUN, creatinine, cholesterol, creatine phosphokinase, and glutamic pyruvic transaminase levels were detected using a FujiFilm Serum Biochemistry Analyzer specific for experimental animals.

Isolation of Primary Renal Glomeruli and Podocyte Cultures

Primary glomeruli were harvested using magnetic isolation protocols, as previously described.43 Briefly, animals receiving Dynabead M-450 perfusions were euthanized, and their kidneys were coarsely dissected and then filtered through a 100-mesh sterile stainless sieve. Dynabead-trapped glomeruli were subjected to magnetic isolation, collagenase digestion, washing with PBS, and further magnetic isolation. In some experiments, primary podocyte cultures were isolated according to previous protocols.44 Briefly, isolated glomeruli were incubated in flask containing RPMI 1640 for 7 days. Outgrowing epithelial cells were trypsinized, filtered through a 33-µm sieve, and then incubated in RPMI 1640 with 10% FBS at 37°C. Isolated cell cultures displayed podocyte marker WT-1 and nephrin.44

Quantitative RT-PCR

Total miR in primary glomeruli or podocyte cultures were isolated (BioChain Institute, Inc., Hayward, CA) and reverse transcribed into cDNA (Ambion, Inc., Austin, TX). Aliquots of cDNA templates were mixed with a PCR mixture containing miR-29a, miR-29b, miR-29c, or U6 primers (Applied Biosystems, Foster City, CA) and a 2× TaqMan Universal PCR Master Mix and an ABI 7900 Detection System (Applied Biosystems). Fold change for the treatment was calculated as 2−ΔΔCt, where ΔΔCt=ΔCtDM–ΔCtcontrol and ΔCt=Cttarget–CtU6.

Liquid Chromatography and Mass Spectrometry

Protein bands of interest in SDS-PAGE gels were cut and digested with 20 ng/ml trypsin. Peptide sequences in the digestion products were separated by an Acclaim PepMap 100 column in liquid chromatographer (UltiMate 3000; Dionex, Sunnyvale, CA) and identified by electrospray ionization mass spectrometry (Bruker Daltonik GmbH, Leipzig, Germany) according to the manufacturer’s instructions. The peptide mass data were matched via the National Center for Biotechnology Information or SwissPort bioinformatics stations. Each tandem mass spectrometry ion with molecular weight search scores ≥39 of the match peptide was considered to have high homology with the candidate proteins.

Immunoprecipitation and Immunoblotting

Tissue and cell lysates from glomeruli and podocyte cultures were extracted. Aliquots of lysates were immunoblotted and probed by H3K9Ac and actin monoclonal antibodies (Millipore, Billerica, MA). In some experiments, lysates were immunoprecipitated using nephrin monoclonal antibodies (R&D Systems, Minneapolis, MN). Nephrin immunocomplexes were immunoblotted and probed by HADC4, HDAC7a, PACF, acetylated lysine, and ubiquitin mAbs and followed by horseradish peroxidase–conjugated IgG and visualization with chemiluminescence agents.

In Situ Hybridization, Immunohistochemistry, and Immunofluorescence

Specimens were fixed and sectioned in RNase-free conditions. In situ hybridization for miR-29a, miR-29b, and miR-29c transcripts was performed using IsHyb In Situ Hybridization kits (Biochain) and digoxigenin-labeled miR-29a probes (Exiquon A/S, Vedbaek, Denmark), as previously described.45 The miR-29a transcripts were visualized by digoxigenin antibody–conjugated horseradish peroxidase and counterstaining with hematoxylin. Desmin immunostaining in specimens were probed by desmin mAb (Cell Signaling Technology, Danvers, MA) and a horseradish peroxidase-3′-3′-diaminobenzidine kit (BioGenex, San Ramon, CA). Sections without primary antibodies were enrolled as negative controls for immunostaining. Apoptotic cell maker TUNEL stains in specimens were detected using in situ cell death detection kits (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. In some experiments, specimens were subjected to immunofluorescence staining probed by nephrin, acetylated lysine mAbs as primary antibody, and followed by fluorescence FITC and Rhodamin (Abcam, Cambridge, MA) as secondary antibodies and then counterstained with 4′,6-diamidino-2-phenylindole (DAKO, Carpinteria, CA).

Histomorphometry

Ten glomeruli in each section were randomly selected for microscopy under ×200 magnification (Carl Zeiss, Gottingen, Germany). Six regions within renal glomeruli from three sections obtained from six mice were detected. The positive immunolabeled and total cells per high-power field in each section were counted, and the percentage of positive labeled cells was calculated.

In Vitro High Glucose–Treated Podocyte Cultures

Primary mouse podocytes (5×105 cells per well, six-well plate) were incubated in RPMI 1640 with 10% FBS in the presence or absence of 25 mM d-glucose or mannitol at 37°C for 48 hours. Immortalized mouse podocyte cell lines were grown as previously described46 and incubated in the presence or absence of 25 mM d-glucose at 37°C for 48 hours. In some experiments, subconfluent podocyte cultures were transfected with miR-29a precursor or empty vector by 109 pfu/ml lentivirus-mediated constructs or HDAC4 siRNA or scrambled control by Lipofectamine 2000 according to the manufacturer’s instructions.

Protein Ligation Assay

Cell cultures were fixed by cold methanol and probed using Duolink II Fluorescence kits (Olink Bioscience, Uppsala, Sweden) with HDAC4 and nephrin antibodies and followed by Duolink proximity ligation assay. After ligation and amplification solution rinses, specimens were counterstained by 4′,6-diamidino-2-phenylindole. Specimens displaying red fluorescence reactions indicate intensive ligation between HDAC4 and nephrin.

Chromatin Immunoprecipitation

Chromatin in the nuclear extracts of cell cultures was sonicated and immunoprecipitated using H3K9Ac mAbs, IgG, and Megan ChIP A/G kits (Millipore), according to the manufacturer’s instructions. DNA in the immunoprecipitate were eluted by chromatin immunoprecipitation solution buffer and digested by proteinase K. DNA was subjected to purification and PCR amplification using Cy3-labeled probes (forward: 5′-ACGACAGATTGAAGGCCTGGG-3′; reverse: 5′-GGTGCTCTT- CCCCAATCAT-3′) (Applied Biosystems) for the miR-29a proximal promoter. Enrichment of H3K9Ac in the miR-29a promoter region of interest was calculated as the input percentage, as previously described.47

Statistical Analyses

All values were expressed as means±SEs. In vitro experimental data were collected from at least three repeated experiments. Parametric ANOVA and a Bonferroni post hoc test were used to analyze the differences among various groups.

Disclosures

None.

Acknowledgments

The authors thank the Center for Laboratory Animals and Core Laboratory of Proteomics and Genomics, Kaohsiung Chang Gung Memorial Hospital, for the use of their facilities.

This work was supported in part by grants from the National Science Council (NSC101-2314-B-182A-115-MY3), the National Health Research Institute (NHRI-EX102-10140EI and NHRI-EX103-10335NI), and Chang Gung Memorial Hospital, Taiwan (CMRPG6G0031, CMRPG6B0402, and CMRPG8B08711).

Footnotes

References

  1. ↵
    1. Yuen DA,
    2. Stead BE,
    3. Zhang Y,
    4. White KE,
    5. Kabir MG,
    6. Thai K,
    7. Advani SL,
    8. Connelly KA,
    9. Takano T,
    10. Zhu L,
    11. Cox AJ,
    12. Kelly DJ,
    13. Gibson IW,
    14. Takahashi T,
    15. Harris RC,
    16. Advani A
    : eNOS deficiency predisposes podocytes to injury in diabetes. J Am Soc Nephrol 23: 1810–1823, 2012pmid:22997257
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Dai C,
    2. Stolz DB,
    3. Kiss LP,
    4. Monga SP,
    5. Holzman LB,
    6. Liu Y
    : Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol 20: 1997–2008, 2009pmid:19628668
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Herman-Edelstein M,
    2. Thomas MC,
    3. Thallas-Bonke V,
    4. Saleem M,
    5. Cooper ME,
    6. Kantharidis P
    : Dedifferentiation of immortalized human podocytes in response to transforming growth factor-β: A model for diabetic podocytopathy. Diabetes 60: 1779–1788, 2011pmid:21521871
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Wang H,
    2. Madhusudhan T,
    3. He T,
    4. Hummel B,
    5. Schmidt S,
    6. Vinnikov IA,
    7. Shahzad K,
    8. Kashif M,
    9. Muller-Krebs S,
    10. Schwenger V,
    11. Bierhaus A,
    12. Rudofsky G,
    13. Nawroth PP,
    14. Isermann B
    : Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: Protective effect of factor V Leiden in diabetic nephropathy. Blood 117: 5231–5242, 2011pmid:21389321
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Mima A,
    2. Kitada M,
    3. Geraldes P,
    4. Li Q,
    5. Matsumoto M,
    6. Mizutani K,
    7. Qi W,
    8. Li C,
    9. Leitges M,
    10. Rask-Madsen C,
    11. King GL
    : Glomerular VEGF resistance induced by PKCδ/SHP-1 activation and contribution to diabetic nephropathy. FASEB J 26: 2963–2974, 2012pmid:22499584
    OpenUrlCrossRefPubMed
  6. ↵
    1. Wang W,
    2. Wang Y,
    3. Long J,
    4. Wang J,
    5. Haudek SB,
    6. Overbeek P,
    7. Chang BH,
    8. Schumacker PT,
    9. Danesh FR
    : Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metab 15: 186–200, 2012pmid:22326220
    OpenUrlCrossRefPubMed
  7. ↵
    1. Welsh GI,
    2. Saleem MA
    : Nephrin-signature molecule of the glomerular podocyte? J Pathol 220: 328–337, 2010pmid:19950250
    OpenUrlCrossRefPubMed
  8. ↵
    1. Hussain S,
    2. Romio L,
    3. Saleem M,
    4. Mathieson P,
    5. Serrano M,
    6. Moscat J,
    7. Diaz-Meco M,
    8. Scambler P,
    9. Koziell A
    : Nephrin deficiency activates NF-kappaB and promotes glomerular injury. J Am Soc Nephrol 20: 1733–1743, 2009pmid:19497968
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Inoki K,
    2. Mori H,
    3. Wang J,
    4. Suzuki T,
    5. Hong S,
    6. Yoshida S,
    7. Blattner SM,
    8. Ikenoue T,
    9. Rüegg MA,
    10. Hall MN,
    11. Kwiatkowski DJ,
    12. Rastaldi MP,
    13. Huber TB,
    14. Kretzler M,
    15. Holzman LB,
    16. Wiggins RC,
    17. Guan KL
    : mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 121: 2181–2196, 2011pmid:21606597
    OpenUrlCrossRefPubMed
  10. ↵
    1. Liu W,
    2. Zhang Y,
    3. Hao J,
    4. Liu S,
    5. Liu Q,
    6. Zhao S,
    7. Shi Y,
    8. Duan H
    : Nestin protects mouse podocytes against high glucose-induced apoptosis by a Cdk5-dependent mechanism. J Cell Biochem 113: 3186–3196, 2012pmid:22614921
    OpenUrlCrossRefPubMed
  11. ↵
    1. Qin XS,
    2. Tsukaguchi H,
    3. Shono A,
    4. Yamamoto A,
    5. Kurihara H,
    6. Doi T
    : Phosphorylation of nephrin triggers its internalization by raft-mediated endocytosis. J Am Soc Nephrol 20: 2534–2545, 2009pmid:19850954
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Tossidou I,
    2. Teng B,
    3. Drobot L,
    4. Meyer-Schwesinger C,
    5. Worthmann K,
    6. Haller H,
    7. Schiffer M
    : CIN85/RukL is a novel binding partner of nephrin and podocin and mediates slit diaphragm turnover in podocytes. J Biol Chem 285: 25285–25295, 2010pmid:20457601
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Weinhold B,
    2. Sellmeier M,
    3. Schaper W,
    4. Blume L,
    5. Philippens B,
    6. Kats E,
    7. Bernard U,
    8. Galuska SP,
    9. Geyer H,
    10. Geyer R,
    11. Worthmann K,
    12. Schiffer M,
    13. Groos S,
    14. Gerardy-Schahn R,
    15. Münster-Kühnel AK
    : Deficits in sialylation impair podocyte maturation. J Am Soc Nephrol 23: 1319–1328, 2012pmid:22745475
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Quack I,
    2. Woznowski M,
    3. Potthoff SA,
    4. Palmer R,
    5. Königshausen E,
    6. Sivritas S,
    7. Schiffer M,
    8. Stegbauer J,
    9. Vonend O,
    10. Rump LC,
    11. Sellin L
    : PKC alpha mediates beta-arrestin2-dependent nephrin endocytosis in hyperglycemia. J Biol Chem 286: 12959–12970, 2011pmid:21321125
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Mihaylova MM,
    2. Vasquez DS,
    3. Ravnskjaer K,
    4. Denechaud PD,
    5. Yu RT,
    6. Alvarez JG,
    7. Downes M,
    8. Evans RM,
    9. Montminy M,
    10. Shaw RJ
    : Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 145: 607–621, 2011pmid:21565617
    OpenUrlCrossRefPubMed
  16. ↵
    1. Sando R 3rd,
    2. Gounko N,
    3. Pieraut S,
    4. Liao L,
    5. Yates J 3rd,
    6. Maximov A
    : HDAC4 governs a transcriptional program essential for synaptic plasticity and memory. Cell 151: 821–834, 2012pmid:23141539
    OpenUrlCrossRefPubMed
  17. ↵
    1. Li J,
    2. Chen J,
    3. Ricupero CL,
    4. Hart RP,
    5. Schwartz MS,
    6. Kusnecov A,
    7. Herrup K
    : Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia. Nat Med 18: 783–790, 2012pmid:22466704
    OpenUrlCrossRefPubMed
  18. ↵
    1. Yuan JH,
    2. Yang F,
    3. Chen BF,
    4. Lu Z,
    5. Huo XS,
    6. Zhou WP,
    7. Wang F,
    8. Sun SH
    : The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. Hepatology 54: 2025–2035, 2011pmid:21837748
    OpenUrlCrossRefPubMed
  19. ↵
    1. Van Beneden K,
    2. Geers C,
    3. Pauwels M,
    4. Mannaerts I,
    5. Verbeelen D,
    6. van Grunsven LA,
    7. Van den Branden C
    : Valproic acid attenuates proteinuria and kidney injury. J Am Soc Nephrol 22: 1863–1875, 2011pmid:21868496
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Gilbert RE,
    2. Huang Q,
    3. Thai K,
    4. Advani SL,
    5. Lee K,
    6. Yuen DA,
    7. Connelly KA,
    8. Advani A
    : Histone deacetylase inhibition attenuates diabetes-associated kidney growth: Potential role for epigenetic modification of the epidermal growth factor receptor. Kidney Int 79: 1312–1321, 2011pmid:21389970
    OpenUrlCrossRefPubMed
  21. ↵
    1. Esteller M
    : Non-coding RNAs in human disease. Nat Rev Genet 12: 861–874, 2011pmid:22094949
    OpenUrlCrossRefPubMed
  22. ↵
    1. Krupa A,
    2. Jenkins R,
    3. Luo DD,
    4. Lewis A,
    5. Phillips A,
    6. Fraser D
    : Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 21: 438–447, 2010pmid:20056746
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Qin W,
    2. Chung AC,
    3. Huang XR,
    4. Meng XM,
    5. Hui DS,
    6. Yu CM,
    7. Sung JJ,
    8. Lan HY
    : TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol 22: 1462–1474, 2011pmid:21784902
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Winbanks CE,
    2. Wang B,
    3. Beyer C,
    4. Koh P,
    5. White L,
    6. Kantharidis P,
    7. Gregorevic P
    : TGF-beta regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4. J Biol Chem 286: 13805–13814, 2011pmid:21324893
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Liu S,
    2. Wu LC,
    3. Pang J,
    4. Santhanam R,
    5. Schwind S,
    6. Wu YZ,
    7. Hickey CJ,
    8. Yu J,
    9. Becker H,
    10. Maharry K,
    11. Radmacher MD,
    12. Li C,
    13. Whitman SP,
    14. Mishra A,
    15. Stauffer N,
    16. Eiring AM,
    17. Briesewitz R,
    18. Baiocchi RA,
    19. Chan KK,
    20. Paschka P,
    21. Caligiuri MA,
    22. Byrd JC,
    23. Croce CM,
    24. Bloomfield CD,
    25. Perrotti D,
    26. Garzon R,
    27. Marcucci G
    : Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 17: 333–347, 2010pmid:20385359
    OpenUrlCrossRefPubMed
  26. ↵
    1. Lin CL,
    2. Wang FS,
    3. Hsu YC,
    4. Chen CN,
    5. Tseng MJ,
    6. Saleem MA,
    7. Chang PJ,
    8. Wang JY
    : Modulation of notch-1 signaling alleviates vascular endothelial growth factor-mediated diabetic nephropathy. Diabetes 59: 1915–1925, 2010pmid:20522599
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Pichaiwong W,
    2. Hudkins KL,
    3. Wietecha T,
    4. Nguyen TQ,
    5. Tachaudomdach C,
    6. Li W,
    7. Askari B,
    8. Kobayashi T,
    9. O’Brien KD,
    10. Pippin JW,
    11. Shankland SJ,
    12. Alpers CE
    : Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. J Am Soc Nephrol 24: 1088–1102, 2013pmid:23641056
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Du B,
    2. Ma LM,
    3. Huang MB,
    4. Zhou H,
    5. Huang HL,
    6. Shao P,
    7. Chen YQ,
    8. Qu LH
    : High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett 584: 811–816, 2010pmid:20067797
    OpenUrlCrossRefPubMed
  29. ↵
    1. Wang XH,
    2. Hu Z,
    3. Klein JD,
    4. Zhang L,
    5. Fang F,
    6. Mitch WE
    : Decreased miR-29 suppresses myogenesis in CKD. J Am Soc Nephrol 22: 2068–2076, 2011pmid:21965375
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Wang B,
    2. Komers R,
    3. Carew R,
    4. Winbanks CE,
    5. Xu B,
    6. Herman-Edelstein M,
    7. Koh P,
    8. Thomas M,
    9. Jandeleit-Dahm K,
    10. Gregorevic P,
    11. Cooper ME,
    12. Kantharidis P
    : Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol 23: 252–265, 2012pmid:22095944
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Long J,
    2. Wang Y,
    3. Wang W,
    4. Chang BH,
    5. Danesh FR
    : MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem 286: 11837–11848, 2011pmid:21310958
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Wang G,
    2. Kwan BC,
    3. Lai FM,
    4. Chow KM,
    5. Li PK,
    6. Szeto CC
    : Urinary miR-21, miR-29, and miR-93: Novel biomarkers of fibrosis. Am J Nephrol 36: 412–418, 2012pmid:23108026
    OpenUrlCrossRefPubMed
  33. ↵
    1. George B,
    2. Verma R,
    3. Soofi AA,
    4. Garg P,
    5. Zhang J,
    6. Park TJ,
    7. Giardino L,
    8. Ryzhova L,
    9. Johnstone DB,
    10. Wong H,
    11. Nihalani D,
    12. Salant DJ,
    13. Hanks SK,
    14. Curran T,
    15. Rastaldi MP,
    16. Holzman LB
    : Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease. J Clin Invest 122: 674–692, 2012pmid:22251701
    OpenUrlCrossRefPubMed
  34. ↵
    1. Kajiho Y,
    2. Harita Y,
    3. Kurihara H,
    4. Horita S,
    5. Matsunaga A,
    6. Tsurumi H,
    7. Kanda S,
    8. Sugawara N,
    9. Miura K,
    10. Sekine T,
    11. Hattori S,
    12. Hattori M,
    13. Igarashi T
    : SIRPα interacts with nephrin at the podocyte slit diaphragm. FEBS J 279: 3010–3021, 2012pmid:22747997
    OpenUrlCrossRefPubMed
  35. ↵
    1. Chen S,
    2. Bellew C,
    3. Yao X,
    4. Stefkova J,
    5. Dipp S,
    6. Saifudeen Z,
    7. Bachvarov D,
    8. El-Dahr SS
    : Histone deacetylase (HDAC) activity is critical for embryonic kidney gene expression, growth, and differentiation. J Biol Chem 286: 32775–32789, 2011pmid:21778236
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Geng H,
    2. Harvey CT,
    3. Pittsenbarger J,
    4. Liu Q,
    5. Beer TM,
    6. Xue C,
    7. Qian DZ
    : HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia. J Biol Chem 286: 38095–38102, 2011pmid:21917920
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Anokye-Danso F,
    2. Trivedi CM,
    3. Juhr D,
    4. Gupta M,
    5. Cui Z,
    6. Tian Y,
    7. Zhang Y,
    8. Yang W,
    9. Gruber PJ,
    10. Epstein JA,
    11. Morrisey EE
    : Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 8: 376–388, 2011pmid:21474102
    OpenUrlCrossRefPubMed
  38. ↵
    1. Rivetti di Val Cervo P,
    2. Lena AM,
    3. Nicoloso M,
    4. Rossi S,
    5. Mancini M,
    6. Zhou H,
    7. Saintigny G,
    8. Dellambra E,
    9. Odorisio T,
    10. Mahe C,
    11. Calin GA,
    12. Candi E,
    13. Melino G
    : p63-microRNA feedback in kerationcyte senescence. Proc Natl Acad Sci U S A 109: 1133–1138, 2012
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Sampath D,
    2. Liu C,
    3. Vasan K,
    4. Sulda M,
    5. Puduvalli VK,
    6. Wierda WG,
    7. Keating MJ
    : Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 119: 1162–1172, 2012pmid:22096249
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Qi Z,
    2. Fujita H,
    3. Jin J,
    4. Davis LS,
    5. Wang Y,
    6. Fogo AB,
    7. Breyer MD
    : Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 54: 2628–2637, 2005pmid:16123351
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Lin CL,
    2. Wang JY,
    3. Ko JY,
    4. Huang YT,
    5. Kuo YH,
    6. Wang FS
    : Dickkopf-1 promotes hyperglycemia-induced accumulation of mesangial matrix and renal dysfunction. J Am Soc Nephrol 21: 124–135, 2010pmid:20019166
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Hsiao YC,
    2. Chang HH,
    3. Tsai CY,
    4. Jong YJ,
    5. Horng LS,
    6. Lin SF,
    7. Tsai TF
    : Coat color-tagged green mouse with EGFP expressed from the RNA polymerase II promoter. Genesis 39: 122–129, 2004pmid:15170698
    OpenUrlCrossRefPubMed
  43. ↵
    1. Takemoto M,
    2. Asker N,
    3. Gerhardt H,
    4. Lundkvist A,
    5. Johansson BR,
    6. Saito Y,
    7. Betsholtz C
    : A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 161: 799–805, 2002pmid:12213707
    OpenUrlCrossRefPubMed
  44. ↵
    1. Golos M,
    2. Lewko B,
    3. Bryl E,
    4. Witkowski JM,
    5. Dubaniewicz A,
    6. Olszewska A,
    7. Latawiec E,
    8. Angielski S,
    9. Stepinski J
    : Effect of angiotensin II on ANP-dependent guanylyl cyclase activity in cultured mouse and rat podocytes. Kidney Blood Press Res 25: 296–302, 2002pmid:12435875
    OpenUrlCrossRefPubMed
  45. ↵
    1. Ko JY,
    2. Wu RW,
    3. Kuo SJ,
    4. Chen MW,
    5. Yeh DW,
    6. Ke HC,
    7. Wu SL,
    8. Wang FS
    : Cannabinoid receptor 1 mediates glucocorticoid-induced bone loss in rats by perturbing bone mineral acquisition and marrow adipogenesis. Arthritis Rheum 64: 1204–1214, 2012pmid:22127784
    OpenUrlCrossRefPubMed
  46. ↵
    1. Mundel P,
    2. Reiser J,
    3. Zúñiga Mejía Borja A,
    4. Pavenstädt H,
    5. Davidson GR,
    6. Kriz W,
    7. Zeller R
    : Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 236: 248–258, 1997pmid:9344605
    OpenUrlCrossRefPubMed
  47. ↵
    1. de Medeiros RB
    : Sequential chromatin immunoprecipitation assay and analysis. Methods Mol Biol 791: 225–237, 2011pmid:21913083
    OpenUrlCrossRefPubMed
View Abstract
Back to top

In this issue

View Selected Citations (0)
Print
Download PDF
Email Article
Citation Tools
Request Permissions
MicroRNA-29a Promotion of Nephrin Acetylation Ameliorates Hyperglycemia-Induced Podocyte Dysfunction
Chun-Liang Lin, Pei-Hsien Lee, Yung-Chien Hsu, Chen-Chou Lei, Jih-Yang Ko, Pei-Chin Chuang, Yu-Ting Huang, Shao-Yu Wang, Shin-Long Wu, Yu-Shan Chen, Wen-Chih Chiang, Jochen Reiser, Feng-Sheng Wang
JASN Aug 2014, 25 (8) 1698-1709; DOI: 10.1681/ASN.2013050527
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section